UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): September 30, 2004
Access Pharmaceuticals, Inc.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-9314 83-0221517
- ------------------------ ------------------------ -------------------
(State of Incorporation) (Commission File Number) (I.R.S. Employer
Identification No.)
2600 Stemmons Freeway, Suite 176, Dallas, Texas 75207
----------------------------------------------- ---------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (214) 905-5100
--------------
Item 8.01 Other Events
------------
On October 1, 2004, Access Pharmaceuticals, Inc. announced that the results
from the Phase I clinical trial of AP5346 a DACH Platinum Polymer Therapeutic
were presented on Friday, October 1, 2004 at the 16th EORTC-NCI-AACR
Symposium in Geneva, Switzerland as a poster presentation. A copy of the
press release regarding this announcement is attached as Exhibit 99.1 and is
incorporated into this current report by reference.
Item 9.01 Financial Statements Information and Exhibits.
----------------------------------------------
(c) Exhibits
--------
99.1 Press Release of Access Pharmaceuticals, Inc. dated October 1, 2004.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
Access Pharmaceuticals, Inc.
(Registrant)
By: /s/ Stephen B. Thompson
------------------
Stephen B. Thompson
Vice President and
Chief Financial Officer
Dated October 1, 2004
3
EXHIBIT INDEX
Exhibit
Number Description
- ------- ------------
99.1 Press Release of Access Pharmaceuticals, Inc. dated October 1, 2004
4